EXELPhase 3 Readout
STELLAR pivotal study top-line data
Exelixis | Zanzalintinib | Renal cell carcinoma
Catalyst details
Late-stage oncology catalyst monitored with SEC and press release updates.
Phase
Phase 3
Expected date
2026-09-30
Expected period
2H 2026
Source type
manual
half yearupcoming
Source URLNotes
This record is structured for public-source tracking and manual analyst override. The database stores date confidence separately from exact dates so quarter, half-year, and estimated guidance can be handled without inventing precision.
Open company detailHistory of changes
No sample changes for this catalyst.